Home › Celgene Upgraded By Credit Suisse, Market Shrugs; More Biotech Upside Ahead?
 

Keywords :   


Celgene Upgraded By Credit Suisse, Market Shrugs; More Biotech Upside Ahead?

2013-12-11 13:26:51| Biotech - Topix.net

We are raising 2017 total sales and EPS to $13B and $16.00 . The largest change to our model is an increase in Revlimid sales to $7.6B due to lengthening of treatment duration and increasing penetration in the first-line setting following positive MM-020 presented over the weekend at the ASH Meeting.

Tags: market credit ahead suisse

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 3
29.06Tropical Storm Beryl Public Advisory Number 3
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Wind Speed Probabilities Number 3
29.06Tropical Storm Beryl Forecast Advisory Number 3
29.06Eastern North Pacific Tropical Weather Outlook
29.06Atlantic Tropical Weather Outlook
More »